FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2403-2405 December 6, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ezekowitz, M. D. Related Article by Singh, B. N. PubMed Citation

To the Editor: Singh et al. (Sept. 6 issue)¹ conclude that dronedarone is significantly more effective than placebo in decreasing the rate of arrhythmic recurrences in atrial fibrillation. They do not comment on the high 1-year incidence of biological hyperthyroidism in their study: 8.4% in the dronedarone group versus 14.1% in the placebo group (P=0.002). Since about 30% of the patients had been taking amiodarone before they were included in the study, a possible explanation is a delayed side effect of this drug, which can provoke hyperthyroidism several months after its discontinuation.² It is hardly conceivable that dronedarone would provide . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.